Welcome to Cape Pulmonology
At Cape Pulmonology, our goal is to optimize your lung health to improve your everyday quality of life, We have the services of a number of pulmonologists and specialised thoracic surgeons and we hope to provide a personalized review of your pulmonary health. We all take breathing for granted… until you can no longer breath.
Cape Pulmonology specializes in a wide range of lung conditions ranging from emphysema, COPD and asthma to unusual interstitial and infectious lung diseases. Cape Pulmonology is situated at the UCT Lung Institute and UCT Private academic Hospital. We have the services of a number of pulmonologists with the back up of a number of allied staff including critical care, renal, cardiology, neurology and gastro-enterology staff. Cape Pulmonology endorses all the allied professions such as physiotherapy, dietetics and occupational therapy to maximize your respiratory outcomes
Critical to service provision at Cape Pulmonology is attention to detail. We hope by spending that extra time and effort with you, we can improve your lung health. With our onsite radiology and technical equipment, here at Cape Pulmonology we can gain greater insight into your pulmonary status so as to maximize your chance at achieving your optimal lung function. Using state of the art equipment, we can precisely measure your lung function. The data gained from this equipment helps us here at Cape Pulmonology to screen and manage a number of pulmonary conditions.
News From Pulmonologist In Cape Town
Lower Respiratory Tract Infections (LTRI) including Community-acquired Pneumonia (CAP) was the 4th leading cause of death in the world in 2012 according to the World Health organization (WHO). This is particularly relevant in lower income countries where LRTI are the...
Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis
ABSTRACT Bedaquiline is a new antituberculosis agent targeting ATP synthase. This randomized, double-blinded study enrolling 68 sputum smear-positive pulmonary tuberculosis patients evaluated the 14-day early bactericidal activity of daily doses of 100 mg, 200 mg, 300...
New antimycobacterial compound PA 824 show promise in early Phase 2 study in the treatment of tuberculosis
Background New drugs, but also shorter, better-tolerated regimens are needed to tackle the high global burden of tuberculosis complicated by drug resistance and retroviral disease. We investigated new multiple-agent combinations over the first 14 days of treatment to...